To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Albert Assad, M.D
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
177 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ordensklinikum Linz Gmbh Elisabethinen
Linz, Austria
- Universitaetsklinikum St. Poelten
Saint P�LTEN, Austria
- Hanusch-Krankenhaus Der Wiener Gebietskrankenkasse
Vienna, Austria
- Hanusch-Krankenhaus Wiener Gebietskrankenkasse
Vienna, Austria
- A.Z. St.-Jan A.V.
Bruges, Belgium
- Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium
- Grand Hospital de Charleroi
Charleroi, Belgium
- Jessa Ziekenhuis
Hasselt, Belgium
- Az Delta
Roeselare, Belgium
- Affiliated Hospital of Hebei University
Baoding, China
- Peking University People'S Hospital (pkuph) - Institute of Hematology
Beijing, China
- Peking University Third Hospital
Beijing, China
- the First Hospital of Jilin University
Changchun, China
- Xiangya Hospital Central South University
Changsha, China
- Fujian Medical University Union Hospital
Fuzhou, China
- Guangdong Provincial of People Hospital
Guangzhou, China
- Nanfang Hospital
Guangzhou, China
- the First Affiliated Hospital of Zhejiang University
Hangzhou, China
- Harbin Institute of Hematology and Oncology
Harbin, China
- Anhui Provincial Hospital
Hefei, China
- the Affiliated Hospital of Inner Mongolia Medical University
Hohhot, China
- Jinan Central Hospital
Jinan, China
- Lanzhou University Second Hospital
Lanzhou, China
- the First Hospital of Lanzhou University
Lanzhou, China
- Jiangxi Provincial of People Hospital
Nanchang, China
- the First Affiliated Hospital of Nanchang University
Nanchang, China
- Jiangsu Province Hospital
Nanjing, China
- Zhongshan Hospital Fudan University
Shanghai, China
- Shenzhen University Hospital
Shenzhen, China
- the Second Hospital of Hebei Medical University
Shijiazhuang, China
- Tianjin Medical University General Hospital
Tianjin, China
- the First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
- Union Hospital Affiliated To Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
- Yantai Yuhuangding Hospital
Yantai, China
- Henan Provincial Peoples Hospital
Zhengzhou, China
- Aalborg University Hospital
Aalborg, Denmark
- Odense University Hospital
Odense, Denmark
- Helsinki University Central Hospital
Helsinki, Finland
- Centre Hospitalier de Versailles - Hopital Andre Mignot
LE Chesnay-rocquencourt, France
- Centre Hospitalier Universitaire Grenoble Alpes (chu Grenoble Alpes) - Hopital Albert Michallon
La Tronche, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 May 2021
- Primary completion
- 3 Aug 2023
- Completion
- 25 Nov 2024
- Last update posted
- 21 Oct 2025
- Registered enrollment
- 252
- Registry id
- NCT04551066
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.